ORGANIZATION
    US VC Coalition Urges Japan to Rethink Drug Pricing, Labor Rules
    By Tatsuya Otsuka October 13, 2026
    A US venture capital coalition is prodding Japan to take a broader approach to invigorating its drug discovery sector, calling for reforms spanning drug pricing, research funding, and labor regulations to make the country more…

    LATEST

    Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
    October 13, 2026
    Major Japanese, US, and European pharma industry associations reiterated the need to reform Japan’s drug pricing system, including a review of foreign average price adjustments, at the second meeting of a public-private policy subgroup on…
    AbbVie’s TrenibotE Up for Review on Oct. 26, Aquipta on Agenda Too
    October 13, 2026
    AbbVie’s trenibotulinumtoxinE (TrenibotE), a treatment for glabellar lines, or frown lines, will come up for discussion by a key health ministry panel on October 26. If approved, it would become the first type E botulinum…
    Japan Panel to Review Full Approval of Nipro’s Stemirac on October 15
    October 13, 2026
    A Japanese health ministry panel will meet on October 15 to discuss whether to recommend full approval for Nipro’s Stemirac, a stem cell therapy for spinal cord injuries that received conditional, time-limited approval in 2018.The…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COMMENTARY

    Japan Moves to Break Plasma Product Capacity Crunch with Factory Aid
    By Takashi Ebisawa

    Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…

    COLUMN

    Outside the Bubble: Lunch with Pharma Delegates
    By Philip Carrigan

    The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA